Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 22.

Graf, N P; Koelblinger, P; Galliker, N; Conrad, S; Barysch, M; Mangana, J; Dummer, R; Cheng, P F; Goldinger, S M (2019). The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma. Journal of the European Academy of Dermatology and Venerology, 33(4):686-692.

Brüggemann, C; Kirchberger, M C; Goldinger, S M; Weide, B; Konrad, A; Erdmann, M; Schadendorf, D; Croner, R S; Krähenbühl, L; Kähler, K C; Hafner, C; Leisgang, W; Kiesewetter, F; Dummer, R; Schuler, G; Stürzl, M; Heinzerling, L (2017). Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology, 143(10):1977-1984.

Amann, V C; Ramelyte, E; Thurneysen, S; Pitocco, R; Bentele-Jaberg, N; Goldinger, S M; Dummer, R; Mangana, J (2017). Developments in targeted therapy in melanoma. European Journal of Surgical Oncology, 43(3):581-593.

Amann, V C; Hoffmann, D; Mangana, J; Dummer, R; Goldinger, S M (2017). Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. Journal of the European Academy of Dermatology and Venerology, 31(10):1638-1640.

Thurneysen, S; Cheng, P F; Nagel, H W; Kunz, M; Jaberg-Bentele, N; Nägeli, M; Ziegler, M; Guenova, E; Goldinger, S M; Mangana, J; Levesque, M P; Dummer, R (2016). An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel. British Journal of Dermatology, 175(5):966-978.

Kunz, M; Urosevic-Maiwald, M; Goldinger, S M; Frauchiger, A L; Dreier, J; Belloni, B; Mangana, J; Jenni, D; Dippel, M; Cozzio, A; Guenova, E; Kamarachev, J; French, L E; Dummer, R (2016). Efficacy and safety of oral alitretinoin in severe oral lichen planus - results of a prospective pilot study. Journal of the European Academy of Dermatology and Venerology, 30(2):293-298.

Frauchiger, A L; Mangana, J; Rechsteiner, M; Moch, H; Seifert, Burkhardt; Braun, R; Dummer, R; Goldinger, S M (2016). Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status. British Journal of Dermatology, 174(4):823-830.

Hecht, M; Zimmer, L; Loquai, C; et al; Goldinger, S M (2015). Radiosensitization by BRAF inhibitor therapy--mechanism and frequency of toxicity in melanoma patients. Annals of Oncology, 26(6):1238-1244.

Dreier, J; Cheng, P F; Bogdan Alleman, I; Gugger, A; Hafner, J; Tschopp, A; Goldinger, S M; Levesque, M P; Dummer, R (2014). Basal cell carcinomas in a tertiary referral centre: a systematic analysis. British Journal of Dermatology, 171(5):1066-1072.

Dummer, R; Duvic, M; Scarisbrick, J; Olsen, E A; Rozati, S; Eggmann, N; Goldinger, S M; Hutchinson, K; Geskin, L; Illidge, T M; Giuliano, E; Elder, J; Kim, Y H (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Annals of Oncology, 25(9):1807-1812.

Urner-Bloch, U; Urner, M; Stieger, P; Galliker, N; Winterton, N; Zubel, A; Moutouh-de Parseval, L; Dummer, R; Goldinger, S M (2014). Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Annals of Oncology, 25(7):1437-1441.

Schilling, B; Sondermann, W; Zhao, F; Griewank, K G; Livingstone, E; Sucker, A; Zelba, H; Weide, B; Trefzer, U; Wilhelm, T; Loquai, C; Berking, C; Hassel, J; Kähler, K C; Utikal, J; Al Ghazal, P; Gutzmer, R; Goldinger, S M; Zimmer, L; Paschen, A; Hillen, U; Schadendorf, D; Dermatologic Cooperative Oncology Group (2014). Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 25(3):747-753.

Dummer, R; Rinderknecht, J; Goldinger, S M (2012). Ultraviolet A and photosensitivity during vemurafenib therapy. New England Journal of Medicine, 366(5):480-481.

Dummer, R; Goldinger, S M; Cozzio, A; French, L E; Karpova, M B (2012). Cutaneous lymphomas: Molecular pathways leading to new drugs. Journal of Investigative Dermatology, 132(3):517-525.

von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mihic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23(2):531-536.

Dummer, R; Rozati, S; Eggmann, N; Rinderknecht, J; Goldinger, S M (2012). From chemotherapy to targeted treatment. Annals of Oncology, 23(Sup 10):x101-x103.

Goldinger, S M (2012). Ipilimumab zur Behandlung des fortgeschrittenen Melanoms. Swiss Medical Forum, 12(33):639-640.

Goldinger, S M; Romano, E; Michielin, O; Dummer, R (2012). Management und Beurteilung des Ansprechens von Ipilimumab bei Patienten mit Melanom. Swiss Medical Forum, 12(44):851-855.

Imhof, L; Goldinger, S M; Baumann, K; Schad, K; French, L E; Röthlisberger, P; Dummer, R (2011). The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Research, 21(1):80-83.

Dummer, R; Goldinger, S M; Sailer, E; French, L E (2010). Aktuelle Therapie des Melanoms der Haut. Therapeutische Umschau, 67(9):447-452.

Dummer, R; Gobbi, S H; Rinderknecht, J; Goldinger, S M (2010). Zielgerichtete Therapie bei Hautmalignomen. Endlich messbare Erfolge! Swiss Medical Forum, 10(51-52):901-903.

Goldinger, S M; Dummer, R; Schmid, P; Burg, G; Seifert, Burkhardt; Läuchli, S (2007). Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. Journal of the European Academy of Dermatology and Venereology, 21(4):504-508.

This list was generated on Sat Jun 15 13:42:29 2019 CEST.